[
    [
        {
            "time": "2021-10-15",
            "original_text": "Pharma Stock Roundup: Q3 Earnings, Resumption of AZN/JNJ Coronavirus Vaccine Study",
            "features": {
                "keywords": [
                    "Q3 Earnings",
                    "AZN/JNJ",
                    "Coronavirus Vaccine",
                    "Resumption"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 9,
                "Time_Proximity": 10,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-10-16",
            "original_text": "Pharmaceutical Industry Leaders Target Cutting-Edge MS Treatments That Once Were 'Fantasy'",
            "features": {
                "keywords": [
                    "Cutting-Edge",
                    "MS Treatments",
                    "Pharmaceutical Industry"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-10-17",
            "original_text": "Novartis expands KymriahÂ® manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia",
            "features": {
                "keywords": [
                    "Novartis",
                    "Kymriah",
                    "CAR-T",
                    "Asia",
                    "Manufacturing"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]